TRIUMEQ Drug Patent Profile

When do Triumeq patents expire, and when can generic versions of Triumeq launch?

Triumeq is a drug marketed by Viiv Hlthcare and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and fifty-seven patent family members in thirty-five countries.

The generic ingredient in TRIUMEQ is abacavir sulfate; dolutegravir sodium; lamivudine. There are twelve drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the abacavir sulfate; dolutegravir sodium; lamivudine profile page.

DrugPatentWatch^® Generic Entry Outlook for Triumeq

Triumeq was eligible for patent challenges on August 12, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 8, 2030. This may change due to patent challenges or generic licensing.

There have been twenty-five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TRIUMEQ

International Patents:	157
US Patents:	2
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRIUMEQ

Paragraph IV (Patent) Challenges for TRIUMEQ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRIUMEQ	Tablets	abacavir sulfate; dolutegravir sodium; lamivudine	600 mg/50 mg/ 300 mg	205551	5	2017-08-14

US Patents and Regulatory Information for TRIUMEQ

TRIUMEQ is protected by two US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	TRIUMEQ	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET;ORAL	205551-001	Aug 22, 2014		RX	Yes	Yes					Y
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes
Viiv Hlthcare	TRIUMEQ	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET;ORAL	205551-001	Aug 22, 2014		RX	Yes	Yes
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes

International Patents for TRIUMEQ

When does loss-of-exclusivity occur for TRIUMEQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Hong Kong

Japan

Mexico

Russian Federation

Singapore

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRIUMEQ around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	WO2007049675	ＨＩＶインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
Canada	2744019
South Korea	20130133061	POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY
Slovenia	3187225

Supplementary Protection Certificates for TRIUMEQ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2465580	C02465580/01	Switzerland		PRODUCT NAME: CABOTEGRAVIR; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67740 08.10.2021
1874117	C01874117/01	Switzerland		CORRECTION OF OWNER: VIIV HEALTHCARE COMPANY
2465580	C 2021 017	Romania		PRODUCT NAME: CABOTEGRAVIR; NATIONAL AUTHORISATION NUMBER: EU/1/20/1481; DATE OF NATIONAL AUTHORISATION: 20201217; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1481; DATE OF FIRST AUTHORISATION IN EEA: 20201217
0434450	1999C0033	Belgium		PRODUCT NAME: ABACAVIR SULFATE; NATL. REGISTRATION NO/DATE: EU/1/99/112/001 19990708; FIRST REGISTRATION: CH 55048 19990628

Investment Scenario and Fundamentals Analysis for TRIUMEQ

Last updated: February 20, 2026

What is TRIUMEQ?

TRIUMEQ is a combination antiretroviral medication approved for the treatment of HIV-1 infection. It comprises three active ingredients: dolutegravir (an integrase strand transfer inhibitor), abacavir (a nucleoside reverse transcriptase inhibitor), and lamivudine (another nucleoside reverse transcriptase inhibitor). Approved by the FDA in 2014, TRIUMEQ is manufactured by ViiV Healthcare.

Market Overview and Revenue Profile

TRIUMEQ holds a niche within the HIV treatment market, which generated approximately USD 28.2 billion globally in 2020, with double-digit growth projected until 2025 (IMARC Group, 2021). The drug competes in the fixed-dose combination (FDC) segment, primarily against Gilead's Biktarvy and Merck's Simeni.

ViiV Healthcare reported USD 4.66 billion in revenues in 2021, with TRIUMEQ accounting for a sizable share, estimated at 12-15%, translating to USD 560-$700 million annually. The drug's sales are driven by its efficacy, tolerability, and once-daily dosing.

Key Pharmacological and Developmental Aspects

Mechanism of Action:

• Dolutegravir inhibits the HIV integrase enzyme, preventing viral DNA integration into the host genome.
• Abacavir is a guanine analog that inhibits viral reverse transcriptase.
• Lamivudine, a cytidine analog, also inhibits reverse transcriptase.

Resistance Profile:

• Dolutegravir exhibits a high barrier to resistance.
• Abacavir and lamivudine have lower resistance thresholds but benefit from combined use.

Formulation and Delivery:

• Once-daily oral tablet.
• Indicated for treatment-naive adult and pediatric patients weighing at least 25 kg.

Pipeline and Developments:

• No recent significant pipeline updates for TRIUMEQ.
• Focus shifted towards next-generation formulations and complementary therapies.

Competitive Landscape

Product	Active Ingredients	Market Share (2022)	Approval Year	Price Range (USD/month)
Biktarvy	Bictegravir + FTC + TAF	49%	2018	750-800
TRIUMEQ	Dolutegravir + Abacavir + Lamivudine	Estimated 12-15%	2014	700-750
Simeni	Elvitegravir + Cobicistat + FTC + TAF	22%	2017	720-770

TRIUMEQ's market share remains steady but faces pressure from newer agents offering improved tolerability, simplified dosing, or better resistance profiles.

Regulatory and Patent Status

• Patent protection in the U.S. until 2024-2025 (ViiV Healthcare, 2022).
• Patent expirations could facilitate generic competition shortly, impacting revenue.
• Ongoing patent litigation regarding formulation patents may influence timing.

Cost and Pricing Dynamics

The USD 700-$750/month price point aligns with other second-generation HIV agents. Insurance and reimbursement policies influence access, with pharmacy benefit managers (PBMs) favoring drugs with higher margins or lower costs.

Investment Outlook

1. Revenue Stability: TRIUMEQ's sales are sustainaed by its profile as a tolerable, effective treatment for ART-naive patients. Patent expiration in 2024-2025 poses at-risk to revenues unless ViiV Healthcare secures new formulations or indications.

2. Competitive Landscape: Gilead’s Biktarvy strengthens its market share with its favorable resistance profile and tolerability. TRIUMEQ's older ingredients may deterr certain patients from switching; however, the drug maintains relevance due to its established efficacy.

3. Pipeline and Innovation: ViiV appears to prioritize new combination therapies rather than TRIUMEQ reformulation. Absence of pipeline enhancements limits upside potential unless new labeling or indications are granted.

4. Manufacturing and Supply Chain: No known manufacturing issues. Any disruption could impact sales, especially as the patent window narrows.

5. Regulatory Risks: Patent expirations and patent challenges could accelerate entry of generics, decreasing TRIUMEQ’s profitability.

Financial Metrics and Valuation

• Revenue: approx. USD 560-$700 million (2021).
• Operating margins for high-sales HIV drugs typically range from 40-60% (ViiV Healthcare financial reports, 2021).
• Patent expiry risks suggest potential revenue erosion of up to 50% post-2024 unless protected through new formulations or indications.

Key Risks and Opportunities

Risks	Opportunities
Patent expiry before 2025	Potential for new formulations or combination therapies
Competition from newly launched agents	Expanding indications or markets in emerging regions
Pricing pressures in health systems	Cost reductions through generics post-patent expiry

Conclusion

TRIUMEQ remains a mid-tier asset within ViiV's portfolio, with steady revenue but limited long-term growth prospects absent pipeline updates or patent extensions. Its near-term outlook hinges on patent status and competitive dynamics, while its core value resides in its proven efficacy and established adherence.

Key Takeaways

• TRIUMEQ generated about USD 560-$700 million in 2021.
• Patent expiration looming in 2024-2025 risks revenue erosion.
• The competitive landscape favors newer agents with better resistance profiles and tolerability.
• No significant pipeline developments project upside beyond current indications.
• Licensing and patent skirmishes could influence future profit margins.

FAQs

Q1: When does TRIUMEQ's patent expire?
A: Patent protection is expected to expire in late 2024 to early 2025, opening the market to generics.

Q2: What are the main competitors?
A: Biktarvy from Gilead and Simeni from Merck are leading competitors, capturing significant market share.

Q3: Is there potential for TRIUMEQ to gain new indications?
A: Currently, no active pipeline developments target new indications for TRIUMEQ.

Q4: How does TRIUMEQ compare in efficacy?
A: It offers comparable efficacy to other first-line regimens, with high barriers to resistance due to dolutegravir.

Q5: What is the impact of the drug's formulation on marketability?
A: Its once-daily fixed-dose tablet maintains strong adherence, but newer formulations from competitors may offer advantages.

---

References

[1] IMARC Group. (2021). HIV Respiratory Market Report.
[2] ViiV Healthcare. (2022). Patent Portfolio and Legal Status.
[3] U.S. Food and Drug Administration. (2014). TRIUMEQ Approval Letter.
[4] IQVIA. (2022). Global HIV Market Data.